Clinical Trial Update: Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1 [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety, tolerability, and efficacy of GB221 in infants with Spinal Muscular Atrophy Type I; the study is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• GB221

Snippet

Sponsor: Gemma Biotherapeutics | Conditions: Spinal Muscular Atrophy Type I | Phase 1, Phase 2 | Status: RECRUITING